Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pelican: Ad/MG1-MAGEA3 + Pembrolizumab in Advanced Skin Cancers
NCT03773744Phase 1Withdrawn
- Sponsor
- Turnstone Biologics
- Start
- Feb 2020
- Primary completion
- Oct 2020
- Modality
- Prophylactic Vaccines, Viral Vectors, Oncolytic Viruses
01
Overview
Phase 1, open-label trial of Ad-MAGEA3 and mg1-magea3 in melanoma and cutaneous squamous cell carcinoma (cSCC) (2 arms), sponsored by Turnstone Biologics. Primary endpoints: Safety of Ad/MG1-MAGEA3 administration at 6 months and Maximum Tolerated Dose / Maximum Feasible Dose at 5 weeks. Planned start Feb 2020; status: withdrawn.
02
Drugs
Ad-MAGEA3mg1-magea3
03
Conditions
melanomacutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT03773744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03773744.